Medication Adherence And Health-Related Quality Of Life In Patients With Urolithiasis: A Narrative Review

Background: Urolithiasis is one of the most common urological disorders worldwide and is associated with
significant morbidity, recurrent episodes, and healthcare burden. Pharmacological therapy plays a crucial role in
both the acute management and prevention of recurrent kidney stones. However, poor medication adherence
among patients often leads to treatment failure and increased recurrence rates. Additionally, the disease and its
complications have a significant impact on the health-related quality of life (HRQoL) of affected
individuals.Aim/ and Objectives include: This review aims to evaluate the role of pharmacotherapy, medication
adherence, and their influence on health-related quality of life among patients with urolithiasis. The methods we
are using A comprehensive literature search was performed using electronic databases, including PubMed,
Scopus, and Google Scholar, for studies published between 2018 and 2025. Relevant articles focusing on
pharmacological management, adherence patterns, and quality-of-life outcomes in patients with urolithiasis
were included. Results show that the literature suggests pharmacological interventions, such as Potassium
Citrate, Allopurinol, Tamsulosin, and Hydrochlorothiazide, are commonly used for the prevention and
management of urolithiasis. Studies indicate that medication non-adherence remains a major barrier to
successful therapy and contributes to recurrent stone formation and increased hospitalizations. Furthermore,
urolithiasis significantly affects patients’ physical, psychological, and social well-being. Conclusion includes
Improving medication adherence through patient education, pharmacist-led interventions, and optimized
pharmacotherapy may enhance treatment outcomes and improve quality of life in patients with urolithiasis.
Keywords: Urolithiasis, Pharmacotherapy, Medication adherence, Kidney stones, Health-related quality of